Core Insights - Since the implementation of deepening medical reform in 2015 and the centralized procurement policy in 2018, Chinese pharmaceutical companies have accelerated their transition from "generic" to "innovative" [1] - In the first half of this year, China approved 43 innovative drugs, a 59% year-on-year increase, setting a record for the highest number in the same period [1] - The business development (BD) activities have exceeded 50 cases this year, with a total amount surpassing $48 billion, indicating strong momentum in industry integration and global cooperation [1] - China's innovative drug research pipeline accounts for about one-fourth of the global total, with approximately 3,000 clinical trials conducted annually, positioning China at the forefront of global innovative drug research [1] - A number of companies have seized opportunities in innovation research, market expansion, and social responsibility, achieving breakthroughs and scale growth, thus contributing to the high-quality development of the health industry [1] Industry Development Initiatives - To promote outstanding enterprises, innovative technologies, and application cases in the health industry, the 21st Century Economic Report and the 21st Century New Health Research Institute launched the 2025 "Sunshine" Case Selection for the health industry competitiveness research [2] - The case selection focuses on seven evaluation dimensions, including excellence in innovation research and development, BD achievements, innovative drug products, ESG practices, emerging innovative pharmaceutical companies, digital innovation applications, and corporate health management [2][3][4][5][6][7] - Each category has clear and diverse evaluation criteria based on quantifiable data to ensure the scientific and fair nature of the selection results [7] Event Timeline - The application process for the 2025 "Sunshine" Case Selection will run from September 25 to October 12, 2025, with companies required to submit their cases by the deadline [8] - The evaluation process will take place from October 13 to November 3, followed by the announcement of outstanding cases and invitations to the 2025 (9th) Health Industry Forum from November 5 to November 12 [8] - The results will be officially released on November 15 during the 2025 (9th) China Health Industry Forum, which will feature discussions on various hot topics in the innovative drug industry [9]
2025年21世纪大健康产业竞争力研究「阳光」案例启动征选
2 1 Shi Ji Jing Ji Bao Dao·2025-09-25 11:41